Aktis Oncology (NASDAQ:AKTS) Given New $33.00 Price Target at HC Wainwright

Aktis Oncology (NASDAQ:AKTS) had its price objective upped by HC Wainwright from $30.00 to $33.00 in a report published on Tuesday,Benzinga reports. They currently have a buy rating on the technology company’s stock.

Several other research analysts have also issued reports on the company. TD Cowen assumed coverage on Aktis Oncology in a research report on Tuesday, February 3rd. They issued a “buy” rating on the stock. Bank of America assumed coverage on Aktis Oncology in a report on Tuesday, February 3rd. They issued a “buy” rating and a $34.00 price objective for the company. Wall Street Zen raised Aktis Oncology to a “hold” rating in a research note on Saturday, January 17th. Leerink Partners assumed coverage on Aktis Oncology in a research report on Tuesday, February 3rd. They set an “outperform” rating and a $31.00 target price for the company. Finally, JPMorgan Chase & Co. assumed coverage on Aktis Oncology in a research note on Tuesday, February 3rd. They issued an “overweight” rating and a $30.00 price target for the company. Five equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Aktis Oncology presently has a consensus rating of “Buy” and a consensus price target of $32.00.

Aktis Oncology Trading Up 8.2%

Shares of NASDAQ AKTS opened at $17.89 on Tuesday. Aktis Oncology has a fifty-two week low of $14.72 and a fifty-two week high of $29.16. The firm has a 50 day simple moving average of $19.19.

Insider Buying and Selling

In other Aktis Oncology news, major shareholder Vida Ventures Ii, Llc bought 835,000 shares of Aktis Oncology stock in a transaction on Monday, January 12th. The shares were purchased at an average cost of $18.00 per share, for a total transaction of $15,030,000.00. Following the completion of the acquisition, the insider owned 5,671,825 shares in the company, valued at approximately $102,092,850. The trade was a 17.26% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Ecor1 Capital, Llc bought 2,222,222 shares of the firm’s stock in a transaction on Monday, January 12th. The stock was acquired at an average cost of $18.00 per share, with a total value of $39,999,996.00. Following the completion of the purchase, the director owned 4,348,658 shares of the company’s stock, valued at approximately $78,275,844. This trade represents a 104.50% increase in their position. The SEC filing for this purchase provides additional information. Insiders have acquired 6,117,776 shares of company stock worth $110,119,968 over the last ninety days.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.